Delivery of berberine using chitosan/fucoidan-taurine conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier

Marine Drugs

Volumn 12, Issue 11, 2014, Pages 5677-5697

  Wu, Shao Jung ^a   Don, Trong Ming ^b   Lin, Cheng Wei ^c,d   Mi, Fwu Long ^c,d  

^a MING CHI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b TAMKANG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chitosan; Drug delivery; Fucoidan; Nanoparticles; Tight junction

Indexed keywords

BERBERINE; CHITOSAN FUCOIDAN TAURINE CONJUGATE NANOPARTICLE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; NANOCARRIER; NITRIC OXIDE; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHITOSAN; CYTOKINE; DEXTRAN; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; FUCOIDIN; LIPOPOLYSACCHARIDE; NANOPARTICLE; POLYSACCHARIDE; TAURINE;

ANIMAL CELL; ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CELL STIMULATION; COCULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM TIGHT JUNCTION DYSFUNCTION; INTESTINE FLUID; INTESTINE FUNCTION DISORDER; INTESTINE MUCOSA PERMEABILITY; INTESTINE PARAMETERS; MACROPHAGE; MOUSE; MTT ASSAY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAW264.7 CELL LINE; SIMULATION; STOMACH JUICE; STOMACH PH; STOMACH PROTECTION; SULFONATION; SYNTHESIS; TRANSEPITHELIAL ELECTRICAL RESISTANCE; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INTESTINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PERMEABILITY; PH; TIGHT JUNCTION;

BACTERIA (MICROORGANISMS); ZIZIPHUS MAURITIANA;

ANIMALS; BERBERINE; CACO-2 CELLS; CELL LINE; CHITOSAN; COCULTURE TECHNIQUES; CYTOKINES; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; INTESTINES; LIPOPOLYSACCHARIDES; MICE; NANOPARTICLES; NITRIC OXIDE; PERMEABILITY; POLYSACCHARIDES; TAURINE; TIGHT JUNCTIONS;

EID: 84915746365     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12115677     Document Type: Article

References (41)

1. Guo, S.; Al-Sadi, R.; Said, H.M.; Ma, T.Y. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am. J. Pathol. 2013, 182, 375-387.
2. Amin, A.H.; Subbaiah, T.V.; Abbasi, K.M. Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Can. J. Microbiol. 1969, 15, 1067-1076.
3. Kuo, C.L.; Chi, C.W.; Liu, T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004, 203, 127-137.
4. Li, G.X.; Wang, X.M.; Jiang, T.; Gong, J.F.; Niu, L.Y.; Li, N. Berberine prevents damage to the intestinal mucosal barrier during early phase of sepsis in rat through mechanisms independent of the NOD-like receptors signaling pathway. Eur. J. Pharmacol. 2014, 730, 1-7.
5. Cao, M.; Wang, P.; Sun, C; He, W.; Wang, F. Amelioration of IFN-gamma and TNF-alpha-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One 2013, 8, e61944.
6. Gu, L.; Li, N.; Gong, J.; Li, Q.; Zhu, W.; Li, J. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J. Infect. Dis. 2011, 203, 1602-1612.
7. Amasheh, M.; Fromm, A.; Krug, S.M.; Amasheh, S.; Andres, S.; Zeitz, M.; Fromm, M.; Schulzke, J.D. TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling. J. Cell Sci. 2010, 123, 4145-4155.
8. Li, N.; Gu, L.; Qu, L.; Gong, J.; Li, Q.; Zhu, W.; Li, J. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur. J. Pharmacol. Sci. 2010, 40, 1-8.
9. Tan, X.S.; Ma, J.Y.; Feng, R.; Ma, C; Chen, W.J.; Sun, Y.P.; Fu, J.; Huang, M.; He, C.Y.; Shou, J.W.; et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One 2013, 8, e77969.
10. Chang, C.H.; Huang, W.Y.; Lai, C.H.; Hsu, Y.M.; Yao, Y.H.; Chen, T.Y.; Wu, J.Y.; Peng, S.F.; Lin, Y.H. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta. Biomater. 2011, 7, 593-603.
11. Lin, Y.H.; Lin, J.H.; Chou, S.C.; Chang, S J.; Chung, C.C.; Chen, Y.S.; Chang, C.H. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: In vitro and in vivo study. Nanomedicine 2014, 1, 1-15.
12. Muzzarelli, R.A. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Mar. Drugs 2010, 8, 292-312.
13. Sashiwa, H.; Aiba, S.I. Chemically modified chitin and chitosan as biomaterials. Prog. Polym. Sci. 2004, 29, 887-908.
14. Harris, R.; Lecumberri, E.; Heras, A. Chitosan-genipin microspheres for the controlled release of drugs: Clarithromycin, tramadol and heparin. Mar. Drugs 2010, 8, 1750-1762.
15. Eftaiha, A.F.; Qinna, N.; Rashid, I.S.; Al Remawi, M.M.; Al Shami, M.R.; Arafat, T.A.; Badwan, A.A. Bioadhesive controlled metronidazole release matrix based on chitosan and xanthan gum. Mar. Drugs 2010, 8, 1716-1730.
16. Kavianinia, I.; Plieger, P.G.; Kandile, N.G.; Harding, D.R.K. In vitro evaluation of spray-dried chitosan microspheres crosslinked with pyromellitic dianhydride for oral colon-specific delivery of protein drugs. J. Appl. Polym. Sci. 2014, 131, doi:10.1002/app.40514.
17. Korkiatithaweechai, S.; Umsarika, P.; Praphairaksit, N.; Muangsin, N. Controlled release of diclofenac from matrix polymer of chitosan and oxidized konjac glucomannan. Mar. Drugs 2011, 9, 1649-1663.
18. Chen, M.C.; Mi, F.L.; Liao, Z.X.; Hsiao, C.W.; Sonaje, K.; Chung, M.F.; Hsu, L.W.; Sung, H.W. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv. Drug. Deliv. Rev. 2013, 65, 865-879.
19. Ale, M.T.; Mikkelsen, J.D.; Meyer, A.S. Important determinants for fucoidan bioactivity: A critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds. Mar. Drugs 2011, 9, 2106-2130.
20. Li, B.; Lu, F.; Wei, X.; Zhao, R. Fucoidan: Structure and bioactivity. Molecules 2008, 13, 1671-1695.
21. Fitton, J.H. Therapies from fucoidan; multifunctional marine polymers. Mar. Drugs 2011, 9, 1731-1760.
22. Tanoue, T.; Nishitani, Y.; Kanazawa, K.; Hashimoto, T.; Mizuno, M. In vitro model to estimate gut inflammation using co-cultured Caco-2 and RAW264.7 cells. Biochem. Biophys. Res. Commun. 2008, 374, 565-569.
23. Iraha, A.; Chinen, H.; Hokama, A.; Yonashiro, T.; Kinjo, T.; Kishimoto, K.; Nakamoto, M.; Hirata, T.; Kinjo, N.; Higa, F.; et al. Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1. World J. Gastroenterol. 2013, 19, 5500-5507.
24. Hamman, J.H. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar. Drugs 2010, 8, 1305-1322.
25. Murakami, K.; Aoki, H.; Nakamura, S.; Nakamura, S.; Takikawa, M.; Hanzawa, M.; Kishimoto, S.; Hattori, H.; Tanaka, Y.; Kiyosawa, T.; et al. Hydrogel blends of chitin/chitosan, fucoidan and alginate as healing-impaired wound dressings. Biomaterials 2010, 31, 83-90.
26. Venkatesan, J.; Bhatnagar, I.; Kim, S.K. Chitosan-alginate biocomposite containing fucoidan for bone tissue engineering. Mar. Drugs 2014, 12, 300-316.
27. Huang, Y.C.; Liu, T.J. Mobilization of mesenchymal stem cells by stromal cell-derived factor-1 released from chitosan/tripolyphosphate/fucoidan nanoparticles. Acta Biomater. 2012, 8, 1048-1056.
28. Yu, S.H.; Tang, D.W.; Hsieh, H.Y.; Wu, W.S.; Lin, B.X.; Chuang, E.Y.; Sung, H.W.; Mi, F.L. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. Acta Biomater. 2013, 9, 7449-7459.
29. Huang, Y.C.; Li, R.Y. Preparation and characterization of antioxidant nanoparticles composed of chitosan and fucoidan for antibiotics delivery. Mar. Drugs 2014, 12, 4379-4398.
30. Da Silva, L.C.; Garcia, T.; Mori, M.; Sandri, G.; Bonferoni, M.C.; Finotelli, P.V.; Cinelli, L.P.; Caramella, C.; Cabral, L.M. Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity. Int. J. Nanomedicine 2012, 7, 2975-2986.
31. Miao, J.; Fa, Y.; Gu, B.; Zhu, W.; Zou, S. Taurine attenuates lipopolysaccharide-induced dysfunction in mouse mammary epithelial cells. Cytokine 2012, 59, 35-40.
32. Lee, D.U.; Kang, Y.J.; Park, M.K.; Lee, Y.S.; Seo, H.G.; Kim, T.S.; Kim, C.H.; Chang, K.C. Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-alpha, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci. 2003, 73, 1401-1412.
33. Jeong, H.W.; Hsu, K.C.; Lee, J.W.; Ham, M.; Huh, J.Y.; Shin, H.J.; Kim, W.S.; Kim, J.B. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E955-E964.
34. Cheng, M.; Gao, X.; Wang, Y.; Chen, H.; He, B.; Xu, H.; Li, Y.; Han, J.; Zhang, Z. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. Mar. Drugs 2013, 11, 3517-3536.
35. Van der Lubben, I.M.; Verhoef, J.C.; Borchard, G.; Junginger, H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 2001, 14, 201-207.
36. Do, H.; Pyo, S.; Sohn, E.H. Suppression of iNOS expression by fucoidan is mediated by regulation of p38 MAPK, JAK/STAT, AP-1 and IRF-1, and depends on up-regulation of scavenger receptor B1 expression in TNF-alpha-and IFN-gamma-stimulated C6 glioma cells. J. Nutr. Biochem. 2010, 21, 671-679.
37. Mizuno, M.; Nishitani, Y.; Hashimoto, T.; Kanazawa, K. Different suppressive effects of fucoidan and lentinan on IL-8 mRNA expression in in vitro gut inflammation. Biosci. Biotechnol. Biochem. 2009, 73, 2324-2325.
38. Mochizuki, T.; Satsu, H.; Nakano, T.; Shimizu, M. Regulation of the human taurine transporter by TNF-alpha and an anti-inflammatory function of taurine in human intestinal Caco-2 cells. BioFactors 2004, 21, 141-144.
39. Cuzzocrea, S.; Mazzon, E.; de Sarro, A.; Caputi, A.P. Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability. Mol. Med. 2000, 6, 766-778.
40. Rao, R.K.; Baker, R.D.; Baker, S.S.; Gupta, A.; Holycross, M. Oxidant-induced disruption of intestinal epithelial barrier function: Role of protein tyrosine phosphorylation. Am. J. Physiol. 1997, 273, G812-G823.
41. Yu, S.H.; Mi, F.L.; Pang, J.C.; Jiang, S.C.; Kuo, T.H.; Wu, S.J.; Shyu, S.S. Preparation and characterization of radical and pH-responsive chitosan-gallic acid conjugate drug carriers. Carbohydr. Polym. 2011, 84, 794-802.